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Glutamine synthetase (GS) plays an essential role in metabolism by
catalyzing the synthesis of glutamine from glutamate and ammonia.
Our recent study showed that CRBN, a direct protein target for the
teratogenic and antitumor activities of immunomodulatory drugs
such as thalidomide, lenalidomide, and pomalidomide, recognizes an
acetyl degron of GS, resulting in ubiquitylation and degradation of GS
in response to glutamine. Here, we report that valosin-containing
protein (VCP)/p97 promotes the degradation of ubiquitylated GS,
resulting in its accumulation in cells with compromised p97 function.
Notably, p97 is also required for the degradation of all four known
CRBN neo-substrates [Ikaros family zinc finger proteins 1 (IKZF1) and 3
(IKZF3), casein kinase 1α (CK1α), and the translation termination fac-
tor GSPT1] whose ubiquitylation is induced by immunomodulatory
drugs. Together, these data point to an unexpectedly intimate rela-
tionship between the E3 ubiquitin ligase CRL4CRBN and p97 pathways.
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Glutamine plays important roles in many cellular processes,including oxidative metabolism and ATP generation, bio-
synthesis of proteins, lipids, and nucleic acids, and cell growth and
proliferation through the regulation of the mTOR signaling path-
way, translation, and autophagy (1, 2). In mammals, it is the most
abundant amino acid in plasma with a concentration of 0.5–0.9 mM
(3), accounting for ∼20% of its free amino acid pool. Glutamine
synthetase (GS) is the only enzyme that is capable of de novo
synthesis of glutamine and also functions to detoxify glutamate and
ammonia, depending on tissue localization. Skeletal muscles and
lungs are major sites of glutamine synthesis, whereas cells of the gut
and the immune system, such as lymphocytes and macrophages,
consume large amounts of glutamine in plasma (4). GS protects
neurons against excitotoxicity by converting glutamate into gluta-
mine in brain, detoxifies ammonia in liver, and maintains physio-
logic pH in kidney (5). In an attempt to investigate the role of GS in
development, He et al. generated GS-knockout mice and reported
that GS is essential in early embryogenesis, because deletion of the
murine GLUL gene causes lethality at the blastocyst stage (em-
bryonic day 3.5) (6). Interestingly, mouse ES cells maintain pluri-
potency and proliferate when grown in the absence of exogenous
glutamine (7). However, inhibition of GS with the small molecule
methionine sulfoximine (MSO) is sufficient to block the proliferation
of ES cells in glutamine-free medium (7). In humans, congenital
systemic glutamine deficiency caused by homozygous GS muta-
tions results in multiorgan failure and neonatal death (8).
Recent studies highlight the importance of glutamine metabo-
lism in metabolic reprogramming, because many tumor cells dis-
play “glutamine addiction” (9). Activation of oncogenes such as
MYC, KRAS, and HIF1α and/or loss of tumor suppressor genes
including p53 can directly mediate the reprogramming of gluta-
mine metabolism by selectively activating their downstream sig-
naling or metabolic pathways (1, 4, 10, 11). As a result, some
tumor cells require large amounts of exogenous glutamine to
generate building blocks and energy for their growth and survival.
In contrast, various tumor cell lines with high expression levels of
GS enzyme can synthesize glutamine de novo and can grow and
proliferate in the absence of exogenous glutamine (12–14).
Befitting its critical role in nitrogen metabolism, GS activity is
tightly regulated. Pioneering studies by Stadtman’s group (15) and
others demonstrated that bacterial GS is subject to complex
feedback regulation by glutamine and downstream metabolites by
reversible adenylylation and deadenylylation of a specific tyrosine
residue, resulting in the inactivation of GS (16–18). In contrast to
the well-defined regulation of bacterial GS, the molecular mech-
anism underlying the regulation of GS activity in mammalian cells
is poorly understood. Before the discovery of ubiquitin-dependent
proteolysis, it was proposed that glutamine inactivates GS through
an uncharacterized degradation mechanism (19–22). Interestingly,
the C-terminal region of bacterial GS, which contains the tyrosine
that is adenylylated, is missing in mammalian GS. In contrast,
eukaryotic GS has a highly conserved N-terminal extension that
does not exist in prokaryotic GS (23). We recently reported that
endogenous GS protein levels in multiple cell types and different
mouse tissues are negatively regulated by glutamine via the
E3 ubiquitin ligase CRL4CRBN (24). CRBN, a direct protein target
for thalidomide teratogenicity and antitumor activity of immuno-
modulatory drugs, including lenalidomide and pomalidomide and a
novel CRBN modulator CC-885 (25–31), recognizes an acetylated
motif (called an “acetyl degron”) of GS, leading to ubiquitylation
and subsequent degradation of GS in response to glutamine (24).
However, the molecular events that take place at each step of the
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pathway are not well understood. For example, one of the funda-
mental questions is how the ubiquitin–proteasome system (UPS)
manages to degrade individual subunits of a homodecameric
enzyme complex.
Valosin-containing protein (VCP)/p97, a homohexameric AAA
ATPase, promotes a number of cellular processes, including
ubiquitin-dependent protein degradation, endoplasmic reticulum-
associated degradation (ERAD), and autophagy (32). p97 working
in concert with different adaptors mediates the extraction of
ubiquitylated proteins from organelles, chromatin, and protein
complexes and delivers them for proteasome- and autophagy-
mediated protein degradation. One of the major functions of
p97 is thought to be the disassembly of protein complexes, pre-
sumably by converting chemical energy generated from ATP hy-
drolysis into mechanical force used for conformational changes of
target proteins (33). Mutations in p97 cause inclusion body my-
opathy associated with Paget’s disease of bone and frontotemporal
dementia (IBMPFD) (34, 35) and a small fraction of familial
amyotrophic lateral sclerosis (ALS) cases (36). Transgenic and
knockin mouse models have been generated to investigate how
these mutations contribute to the pathogenesis of IBMPFD and
ALS (37–40). Because of its pivotal role in maintaining the cellular
protein homeostasis important for tumor cell growth and survival,
p97 is of particular interest as an anticancer drug target. Recently
we developed the reversible and ATP-competitive p97 inhibitors
DBeQ and ML240 (41, 42). Subsequent optimization of ML240
resulted in the identification of CB-5083 (43), which is currently
being tested in phase I clinical trials. CB-5083 exhibits potent an-
titumor activity in both multiple myeloma and solid tumor xeno-
graft models (44). However, the precise mechanisms by which
p97 regulates substrates under physiological conditions remain
poorly understood, and only a limited number of substrates have
been studied in great detail.
Results
Glutamine Induces GS Disassembly in a Ubiquitylation- and p97-
Dependent Manner. The active sites of the proteasome are
enclosed in a chamber, access to which is governed by portals with
a diameter of ∼13 Å (45, 46). Because this diameter is narrower
than the diameter of most globular proteins, substrates must be
disengaged from binding partners and unfolded before being
threaded into the proteasome’s proteolytic chamber. Because GS
is a homodecamer composed of two pentameric rings stacked
upon each other to form a structure 90 × 110 Å (23), it is not
known how the UPS mediates its glutamine-induced degradation.
It is possible that a high concentration of glutamine can destabilize
the GS oligomer and facilitate the degradation of individual
monomers. To test this idea, we performed a series of gel filtration
experiments with cell lysates prepared from glutamine-starved
cells and glutamine-treated cells in the presence or absence of
different chemical inhibitors. Fractions from each sample were
collected and analyzed by immunoblotting. As shown in Fig. 1A,
endogenous GS eluted primarily as a single peak corresponding to
a homodecameric protein complex (∼440 kDa) in glutamine-
starved cells. Upon glutamine treatment, GS fractionated as a
broader peak with “tails” of both higher and lower molecular
weight (MW), both of which were suppressed by the addition of
the NEDD8-activating enzyme inhibitor MLN4924 (Fig. 1 B–D)
(47). Moreover, glutamine-induced spreading of the GS peak was
also blocked by the GS inhibitor MSO, which inhibited glutamine-
induced GS ubiquitylation and degradation (Fig. S1) (48). In-
terestingly, the p97 inhibitor CB-5083 also blocked glutamine-
induced spreading of the GS peak (Fig. 1D) but did not block
GS ubiquitylation (Fig. 1E). We show later that this effect of CB-
5083 may be caused by the competitive displacement of GS by
other substrates that accumulate upon inhibition of p97. Taken
together, our data suggest that glutamine-triggered GS ubiq-
uitylation may promote the recruitment of p97 to initiate the
disassembly of the decamer, inducing a shift of a fraction of the
GS pool to higher and lower MW, respectively.
p97 Interacts with Endogenous GS and Promotes Degradation of GS
in a Glutamine-Dependent Manner. Based on the above observa-
tions, we hypothesized that p97 may be recruited to ubiquitylated
GS to regulate its degradation. To investigate this hypothesis, we
first performed immunoprecipitation (IP) experiments using an
antibody specific to p97 and found that glutamine greatly enhanced
the binding of endogenous, apparently unubiquitylated GS to en-
dogenous p97 (Fig. 2A). This binding nevertheless was likely de-
pendent on ubiquitylation, because it was greatly reduced by
pretreatment of cells with the pan–Cullin-RING ligase (CRL) in-
hibitor MLN4924 (Fig. 2A). The role of ubiquitylation in GS binding
to p97 is considered in more detail in the next section. GS also was
recovered, albeit in reduced amounts, in p97 immunoprecipitates
from cells treated with the p97 inhibitor CB-5083 following the ac-
tivation of GS degradation (Fig. 2A). We suggest that this reduction
was caused by competition from other p97 substrates that accumu-
lated upon treatment with CB-5083; this notion is consistent with the
observation that much greater amounts of UFD1•NPL4 and high-
MW ubiquitin conjugates coimmunoprecipitated with p97 from cells
treated with CB-5083. In support of this idea, the recovery of GS in
p97 immunoprecipitates was essentially eliminated if a bolus of
p97 substrates was accumulated by CB-5083 treatment before the
activation of GS degradation with glutamine (Fig. S2A; note that the
design of this experiment is similar to that of Fig. 1D).
The enhanced binding of GS to p97 in cells treated with glu-
tamine suggests that p97 might modulate glutamine-induced
degradation of GS. Consistent with this idea, inhibition of p97
by CB-5083 or NMS-873 blocked glutamine-induced GS degra-
dation (Fig. 2 B and C and Fig. S2B). Glutamine-induced GS
degradation also was inhibited upon depletion of p97 by shRNA
knockdown (Fig. 2D and Fig. S2C).
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Fig. 1. Glutamine alters the apparent assembly state of GS in an ubiq-
uitylation- and p97-dependent manner. (A and B) MCF7 cells were starved of
glutamine for 24 h and then were pretreated with (A) or without (B) 2 μM pan
cullin–RING ubiquitin ligase inhibitor MLN4924 for 30 min, followed by the
addition of 4 mM glutamine plus the histone deacetylase (HDAC) inhibitors
suberoylanilide hydroxamic acid (SAHA) (2 μM) and NAM (10 μM) (+Q +HDACi)
or not (−Q −HDACi) for 2 h. Cell lysates were fractionated on a Superdex
200 gel filtration column. Individual fractions were concentrated by tri-
chloroacetic acid (TCA) precipitation and analyzed by SDS/PAGE and immu-
noblotting with the indicated antibodies. (C) As in A and B, except that
H1299 cells were starved of glutamine for 24 h and then were pretreated with
MLN4924 (2 μM) or the GS inhibitor MSO (2 mM) for 30 min, followed by the
addition (or not) of 4 mM glutamine for 2 h. (D) As in A and B, except that
HEK293 cells were starved of glutamine for 24 h and then were pretreated
with MLN4924 (2 μM) or the p97 inhibitor CB-5083 (10 μM) for 30 min, fol-
lowed by the addition (or not) of 4 mM glutamine for 2 h. (E) Fractions 10–12,
prepared from HEK293 cells treated with CB-5083 and glutamine (used in D,
bottom panel), were combined and subjected to pulldown with TUBE2 resin,
followed by treatment with or without USP2. The bound fractions were ana-
lyzed by SDS/PAGE and immunoblotting with antibodies against GS and
ubiquitin. L.E., long exposure; S.E., short exposure; (Ub)n, polyubiquitin.
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Because glutamine promotes GS degradation by the UPS, we
next sought to determine the effect of p97 inactivation on GS
ubiquitylation. We treated glutamine-starved cells with the protea-
some inhibitor MG132 or the p97 inhibitor CB-5083 in the pres-
ence or absence of 4 mM glutamine and then enriched ubiquitin
conjugates on a tandem ubiquitin-binding entity (TUBE2) resin.
Immunoblotting of the bound fraction and input (cell lysate)
with antibodies against GS or ubiquitin revealed that inhibition of
either p97 or the proteasome in glutamine-treated cells resulted
in a significant increase in ubiquitin-conjugated GS forms, which
were deconjugated with the deubiquitylating enzyme ubiquitin
C-terminal hydrolase 2 (USP2) (Fig. 2E and Fig. S3A). A similar
result was obtained upon shRNA knockdown of p97 (Fig. 2F).
Consistent with the results obtained with p97 ATPase inhibitors,
overexpression of the ATPase-deficient p97E578Q mutant (49)
caused accumulation of polyubiquitylated GS upon glutamine ac-
tivation, even though the mutant protein was able to bind GS, al-
beit with slightly reduced efficiency (Fig. S3 D and E).
It is worth noting that substantial amounts of apparently
unubiquitylated GS coprecipitated with p97 (Fig. 2A and Fig.
S2A). However, large amounts of unmodified GS were also
pulled down along with ubiquitylated GS on TUBE2 resin (Fig. 2
E and F and Fig. S3 A and D). The association of apparently
unmodified GS with TUBE2 resin was specific, in that it was
strongly stimulated by glutamine (best seen in Fig. 2E). We
suggest that p97 is recruited to GS decamers that contain a small
number of ubiquitylated GS subunits and a much larger number
of unmodified subunits, to extract the ubiquitylated GS subunits
from the unmodified subunits.
Accumulation of Ubiquitylated GS upon p97 Inhibition Is Dependent
on CRL4CRBN Activity. We recently reported that CRL4CRBN di-
rectly mediates the glutamine-induced ubiquitylation of GS (24).
Next, we tested whether CRL4CRBN and p97 function on the same
pathway to regulate glutamine-induced GS degradation. We rea-
soned that, if p97 functions downstream of CRL4CRBN, the ex-
ceptionally strong accumulation of ubiquitylated GS induced by
p97 inhibitors should be blunted in cells in which CRL4CRBN is
inhibited. To address this issue, MCF7 cells were cotreated with
the p97 inhibitors CB-5083 or NMS-873 with or without the pan-
CRL inhibitor MLN4924 and then were activated with 4 mM
glutamine for 3 h. TUBE2 pulldown experiments showed that the
accumulation of polyubiquitylated GS caused by CB-5083 or
NMS-873 was completely abolished in MLN4924-treated cells
(Fig. 3A). In keeping with the point made in the preceding para-
graph, loss of ubiquitylated GS caused a parallel reduction in the
recovery of apparently unmodified GS on TUBE2 resin. A similar
epistatic effect of MLN4924 was observed in cells depleted of
p97 by shRNA knockdown (Fig. 3B). The effect of MLN4924 was
caused specifically by the inhibition of CRL4CRBN, because accu-
mulation of ubiquitylated GS in response to NMS873 was blunted
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Fig. 2. p97 interacts with endogenous GS and promotes glutamine-induced
degradation of GS. (A) HEK293 cells were starved of glutamine for 24 h, were
pretreated (or not) with MLN4924 (2 μM) for 30 min, and then were treated
(or not) with 4 mM glutamine for 2 h. For CB-5083 treatment, after the ad-
dition of 4 mM glutamine for 90 min, cells were treated with CB-5083 (10 μM)
for 30 min. Protein extracts were immunoprecipitated with mouse IgG control
or p97 antibodies, followed by Western blot analysis with the indicated anti-
bodies. The ratio of GS bound to p97 normalized to input GS is shown. L.E.,
long exposure (the long exposure blot was quantified); S.E., short exposure;
(Ub)n, polyubiquitin. (B and C) MCF7 cells were starved of glutamine for 24 h
and were pretreated with the p97 inhibitors CB-5083 (B) or NMS-873 (C) for
30 min, followed by addition (or not) of 4 mM glutamine for 4 h. Cell extracts
were analyzed by SDS/PAGE and immunoblotting with antibodies against GS,
p97, and GAPDH. The relative ratios of GS:GAPDH, normalized to lane 1, are
shown. (D) HEK293 cells stably expressing doxycycline (Dox)-inducible shRNA
targeting p97 were either mock-treated or induced with doxycycline (1 μg/mL)
for 48 h and then were starved of glutamine for 24 h, followed by the addition
of 4 mM glutamine for the indicated times. Cell lysates were analyzed by SDS/
PAGE and immunoblotting with antibodies against GS, p97, and GAPDH. The
relative ratios of GS:GAPDH, normalized to lane 1, are shown. (E) H1299 cells
were starved of glutamine for 24 h and then were pretreated with MG132
(10 μM) or CB-5083 (10 μM) for 30min, followed by the addition (or not) of 4 mM
glutamine for 3 h. Cell lysates were fractionated on a TUBE2 resin, followed by
treatment with or without USP2. The bound fractions and lysate samples were
analyzed by SDS/PAGE and immunoblotting with antibodies against GS and
ubiquitin. Input is shown in Fig. S3B. (F) HEK293 cells stably expressing
doxycycline-inducible shRNA targeting p97 were mock-treated or were induced
with doxycycline (1 μg/mL) for 48 h and then were starved of glutamine for 24 h,
followed by the addition of 4 mM glutamine for the indicated times. Cell lysates
were fractionated on a TUBE2 resin, and both lysate samples and the bound
fractions were analyzed by SDS/PAGE and immunoblotting with antibodies
against GS, ubiquitin (shown in Fig. S3C), p97, and GAPDH.
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Fig. 3. Inhibition of p97 promotes the accumulation of ubiquitylated GS in
a CRL4CRBN-dependent manner. (A) MCF7 cells were starved of glutamine for
24 h and then were pretreated (or not) with CB-5083 (10 μM), NMS-873
(10 μM), or MLN4924 (2 μM) for 30 min as indicated in the figure, followed
by the addition (or not) of 4 mM glutamine for 3 h. Cell lysates were frac-
tionated on a TUBE2 resin, and both lysate samples and the bound fractions
were analyzed by SDS/PAGE and immunoblotting with antibodies against GS,
ubiquitin, and GAPDH. (Ub)n, polyubiquitin. (B) HEK293 cells stably expressing
doxycycline (Dox)-inducible shRNA targeting p97 were induced with doxycy-
cline (1 μg/mL) for 48 h and then were starved of glutamine for 24 h. Cells were
pretreated (or not) with MLN4924 (2 μM) for 30 min, followed by the addition
(or not) of 4 mM glutamine for 2 h. Cell lysates were fractionated on a
TUBE2 resin, and both lysate samples and the bound fractions were analyzed
by SDS/PAGE and immunoblotting with antibodies against GS, ubiquitin, and
GAPDH. (C) CRBN-KO 293FT cells stably expressing WT FlagCRBN or the in-
dicated mutants were starved of glutamine for 24 h. Cells were pretreated
with NMS-873 (10 μM) for 30 min, followed by the addition (or not) of 4 mM
glutamine for 2 h. Cell lysates were fractionated on a TUBE2 resin, and both
lysate samples and the bound fractions were analyzed by SDS/PAGE and im-
munoblotting with antibodies against GS, ubiquitin, Flag, and GAPDH.
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in CRBN-knockout 293FT cells expressing substrate binding-
defective N351R or W400E mutants of CRBN (Fig. 3C) (24).
The p97 Adaptor Complex UFD1•NPL4 Interacts with Ubiquitylated GS
upon Glutamine Activation.One of the central roles of p97 is to bind
and extract ubiquitylated proteins from stable protein complexes,
membranes, or chromatin (32). This process typically involves
an adaptor protein, which may link ubiquitylated substrates to
p97. To test whether a p97 adaptor participates in glutamine-
induced GS ubiquitylation and degradation, we used siRNAs
to knock down UBX domain-containing protein 7 (UBXD7),
a direct binding partner of cullins 2 (CUL2) and 4 (CUL4) (50,
51), and the heterodimer ubiquitin fusion degradation protein
(UFD1)•nuclear protein localization protein 4 (NPL4), which is
well known to target ubiquitylated substrates for p97-dependent
proteasomal degradation (52, 53). Depletion of UFD1, but not
UBXD7, caused ubiquitylated GS to accumulate upon glutamine
treatment (Fig. 4A), suggesting that UFD1•NPL4 participates in
glutamine-induced GS degradation. Consistent with observations
in the TUBE2 pulldowns, glutamine stimulated the interaction
between UFD1•NPL4 and both ubiquitylated and apparently
unmodified GS (Fig. 4 B and C). Inhibition of proteasome by
MG132 or p97 by CB-5083 significantly enhanced this interaction,
which was abolished by blocking GS ubiquitylation with MLN-
4924 (Fig. 4 B and C). Despite these interactions, depletion of
either UFD1 or NPL4 did not block glutamine-induced degra-
dation of GS (Fig. 4A). Either UFD1•NPL4 plays a facilitating
role that is not essential for GS degradation, or other adaptors can
compensate for UFD1•NPL4 when it is absent.
p97 Mediates the Disassembly of GS upon Inhibition of the
Proteasome. Our observation that p97 binds ubiquitylated GS
and promotes its proteasome-dependent degradation suggests that
p97 might mediate the disassembly of ubiquitylated GS subunits
from a homodecamer, thereby enabling their degradation by the
proteasome. This notion is consistent with the observations
reported in Fig. 1 that the appearance of a low-MW pool of GS
upon gel filtration of cell lysate was dependent upon glutamine,
NEDD8 conjugation, and p97 activity. We next sought to explore
more fully whether p97 mediates glutamine-induced disassembly
of GS by treating MCF7 cells with glutamine in the presence of
proteasome and/or p97 inhibitors. Gel filtration experiments in-
dicated that inhibition of the proteasome accentuated the
glutamine-induced spreading of the GS peak into higher- and
lower-MW complexes and that this spreading was completely
blocked by inhibition of p97 with CB-5083, NMS873, or shRNA
knockdown (Fig. 5A and Fig. S4). The spreading of the GS peak to
lower MW in cells treated with glutamine plus MG132 was likely
caused by the disassembly of the decamer into smaller oligomers;
we suggest that the spreading to higher MW was caused, at least in
part, by the binding of GS to p97, because both proteins coeluted
in high-MW fractions, GS bound p97 and UFD1•NPL4 (Figs. 2A
and 4 B and C), and the high-MW complex was absent when
p97 function was inhibited with small molecules or shRNA
knockdown. As a more robust test of this proposal, we treated
glutamine-starved cells with or without glutamine and fractionated
the cell lysates by gel filtration (Fig. 5B). Fractions from across the
peak of the glutamine-treated sample were subjected to IP with
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Fig. 4. The p97 adaptor complex UFD1•NPL4 interacts with ubiquitylated GS
upon the addition of glutamine. (A) H1299 cells were transfected with control
(CT) siRNA or with siRNAs that target NPL4, UFD1, or UBXD7. Forty-eight hours
after transfection, cells were starved of glutamine for 24 h, followed by the
addition (or not) of 4 mM glutamine for 2 h. Total ubiquitinated proteins were
affinity-purified from cell lysates using TUBE2-agarose. Bound fractions and
cell lysates (input) were analyzed by SDS/PAGE and immunoblotting with the
indicated antibodies. (Ub)n, polyubiquitin. (B and C) HEK293 cells were tran-
siently transfected with empty vector or with plasmids encoding FlagNPL4 (B) or
UFD1Flag (C). After 24-h transfection, cells were starved of glutamine for 24 h
and were pretreated (or not) with MG132 (20 μM), CB-5083 (10 μM), or
MLN4924 (2 μM) for 30 min, followed by the addition (or not) of 4 mM glu-
tamine for 2 h. Cell lysates were immunoprecipitated with anti-Flag resin.
Precipitated and input fractions were analyzed by SDS/PAGE and immuno-
blotting with the indicated antibodies.
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Fig. 5. p97 mediates the disassembly of GS upon inhibition of the protea-
some. (A) MCF7 cells were grown to 80–90% confluence in 15-cm plates and
were starved of glutamine for 24 h. Cells were pretreated (or not) with
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starved of glutamine for 24 h and then were treated with 4 mM glutamine
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filtration column. (Upper) Individual fractions were concentrated by TCA
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anti-p97 followed by immunoblotting for GS. A clear association
of GS with p97 was observed in fractions that correspond to the
high-MW tail of the GS peak.
Immunomodulatory Drug-Induced Degradation of CRBN Neosubstrates
Requires p97. To investigate a potential role for p97 in regulating
the degradation of other CRL4CRBN substrates, we extended
our study to immunomodulatory drug-induced degradation of
CRL4CRBN neosubstrates (28, 29, 54). CB-5083 blocked the
lenalidomide-induced degradation of the lymphoid transcription
factors Ikaros family zinc finger proteins 1 (KZF1) and 3 (IKZF3)
in MM.1S and L363 multiple myeloma cells (Fig. 6 A–C). A
similar blockade of the lenalidomide effect was observed in
MM.1S (Fig. 6D) and U266 (Fig. S5A) cells treated with NMS873.
Control experiments verified that the effect of lenalidomide on
IKZF1 and IKZF3 was CRBN-dependent (Fig. 6 C and D). In-
hibition of p97 with CB-5083 or proteasome with MG132 caused
the accumulation of ubiquitylated IKZF1 regardless of whether
lenalidomide was added (Fig. S5B), suggesting that p97 was re-
quired for both its constitutive and lenalidomide-induced degra-
dation. To ask if p97 inhibition also affects the degradation of other
CRBN neosubstrates induced by the CRBN modulator CC-885, we
examined the effect of CB5083 on CC-885–induced degradation
of the translation termination factor GSPT1 (30). Similar to
MLN4924 and MG132, pretreatment with CB5083 completely
blocked the CC-885–induced degradation of GSPT1 in U937 AML
cells and MM1S myeloma cells (Fig. 6E). Finally, to confirm that
CB5083 was indeed blocking neosubstrate proteolysis, we per-
formed a cycloheximide chase experiment to monitor lenalidomide-
induced degradation of casein kinase 1α (CK1α) (31). As shown in
Fig. 6F, lenalidomide induced rapid loss of CK1α, but this effect
was completely blocked upon inhibition of p97 with CB5083.
Discussion
In this study, we uncover a role for p97 in regulating GS. As il-
lustrated in Fig. 7, glutamine induces CRL4CRBN-dependent ubiq-
uitylation of GS subunits. Subsequently, p97•UFD1•NPL4 binds to
ubiquitylated GS and promotes the disassembly of the homo-
decamer, thereby enabling degradation of the ubiquitylated sub-
units by the proteasome. Currently, we do not know how
acetylation, ubiquitylation, and extraction of individual subunits are
coordinated. Pulldown experiments with a ubiquitin-binding resin
reveal that large amounts of unmodified GS are retrieved in a
manner that depends on factors that promote GS ubiquitylation.
This finding suggests that one or a small number of subunits are
ubiquitylated per homodecamer. Once these subunits are extracted
and degraded by the proteasome, the fate of the remaining un-
modified subunits is unclear, but we anticipate that they reassemble
to form a smaller number of homodecamers. A number of ques-
tions about the mechanism and regulation of GS degradation
remain to be addressed, including the means by which glutamine
levels are monitored, the mechanism by which p97 extracts
ubiquitylated subunits from GS decamers, and the role of adaptor
proteins in this process. Interestingly, bioinformatic analysis of cell
lines from the Cancer Cell Line Encyclopedia (CCLE) (55)
revealed significant covariance between the expression of mRNAs
encoding CRBN and multiple p97 adaptors (Fig. S6), suggesting
diverse functional connections between these pathways.
In the brain, GS is highly expressed in astrocytes and plays a
critical role in regulating the glutamine–glutamate cycle between
astrocytes and neurons (56). In astrocytes, GS combines glutamate
and ammonia to form glutamine, which then is transferred to
neurons and converted to glutamate by mitochondrial glutaminase
(57). Glutamate is sequestered in synaptic vesicles and then is
released as a neurotransmitter into the synaptic cleft, after which it
is taken up by astrocytes to complete the cycle. The excessive
accumulation of glutamate can induce excitotoxicity or neuronal
cell death (58). Notably, it was reported that specific depletion of
GS in murine astrocytes in the brain leads to death at postnatal
day 3 (59). In addition, deregulated GS activity and/or increased
glutamate levels in the cerebrospinal fluid have been implicated in
neurodegenerative diseases, including Alzheimer’s disease, Par-
kinson’s disease, Huntington’s disease, and ALS (60–63). Our
findings that p97 directly controls GS degradation have potential
implications for human diseases, in particular ALS, which is
characterized by the progressive degeneration of motor neurons.
Riluzole, an inhibitor of glutamate release, is the only effective
drug for ALS, and it prolongs survival by 3–6 mo (64). Adminis-
tration of the GS inhibitor MSO to SOD1G93A transgenic mice,
which develop a phenotype similar to ALS in humans, decreases
both glutamine and glutamate levels in the brain and significantly
extends the lifespan of these mice (65, 66). Therefore, it will be of
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Fig. 6. p97 is required for immunomodulatory drug-induced degradation
of CRBN neosubstrates. (A) MM1S cells were pretreated with the indicated
doses of CB-5083 or 1 μM MLN4924 (MLN) for 30 min, followed by the ad-
dition of lenalidomide (Len) (10 μM) for 4 h. Cell lysates were fractionated by
SDS/PAGE and immunoblotted for the indicated endogenous proteins. The
relative ratios of IKZF1:GAPDH or IKZF3, normalized to lane 1, are shown
here and in B–D. (B) L363 cells were pretreated with CB-5083 (2 μM) for
30 min, followed by the addition (or not) of lenalidomide (10 μM) for 4 h.
Cell lysates were fractionated by SDS/PAGE and immunoblotted for the in-
dicated endogenous proteins. (C) MM1S cells stably expressing control (CT)
or CRBN shRNAs were pretreated with CB-5083 (2 μM) for 30 min, followed
by the addition (or not) of lenalidomide (10 μM) for 5 h. Cell lysates were
analyzed by immunoblotting with the indicated antibodies. (D) As in C, ex-
cept that cells were pretreated (or not) with NMS-873 (2 or 5 μM) for 30 min.
(E) U937 and MM1S cells were pretreated (or not) with CB-5083 (2 or 10 μM),
MLN4924 (1 μM), or MG132 (10 μM) for 1 h, followed by treatment with
10 nM CC-885 for an additional 2 h. Whole-cell extracts were subjected to
immunoblot analysis. (F) Cells were pretreated with CB-5083 (2 μM) and/or
lenalidomide (10 μM) for 30 min followed by the addition of cyclohexamide
(CHX) (100 μg/mL). At the indicated times after the addition of cyclo-
hexamide, samples were harvested for immunoblot analysis. The relative
ratios of CK1α:GAPDH, normalized to lane 1, are shown.
Fig. 7. Proposed model for the role of p97 in mediating regulated degra-
dation of CRL4CRBN substrates, including GS and lenalidomide-induced neo-
substrates. For the sake of simplicity, one subunit of GS homodecamer is
ubiquitylated by CRL4CRBN, segregated by the p97–UFD1–NPL4 complex, and
subsequently degraded by the proteasome upon the addition of glutamine.
Ub, ubiquitin.
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particular interest in future studies to investigate whether possible
defects in the degradation of GS and other p97 substrates caused
by p97 mutations identified in ALS patients may contribute to
pathogenesis or serve as early diagnostic markers of the disease.
Recent work has shown that immunomodulatory drugs trigger
CRBN-dependent ubiquitylation of IKZF1, IKZF3, CK1α, and
GSPT1, which is followed by their degradation (28–31, 54). Re-
markably, all these immunomodulatory drug-induced degrada-
tions are dependent on p97. Thus, all five CRBN substrates/
neosubstrates examined in this work exhibit striking dependence
on p97. We know of no other ubiquitylation pathway, other than
ERAD, in which the substrates uniformly exhibit dependence on
p97 for their degradation. This unique feature of CRL4CRBN may
be a coincidental consequence of the oligomerization status of its
known substrates or may point to an obligate functional re-
lationship between these proteins. Further studies are required to
illuminate the role of p97 in regulating immunomodulatory drug-
induced degradation of these CRBN neosubstrates. GSPT1, in a
binary complex with eukaryotic peptide chain release factor sub-
unit 1 (eRF1), functions as a polypeptide chain release factor (67),
whereas IKZF1/3 proteins are known to recruit the Mi-2/
nucleosome remodeling and deacetylase (NuRD) complex to
specific genomic targets (68, 69). By analogy to other degradation
pathways in which p97 plays a critical role (70, 71), it is possible
that p97 mediates the extraction of ubiquitylated GSPT1 from
eRF1 and ubiquitylated IKZF1/3 proteins from chromatin before
their degradation by the proteasome.
Our observations point to an unexpected role for p97 in the
mechanism of action of immunomodulatory drugs, and this role
could have important implications for patient responsiveness to
immunomodulatory drug therapy. CRBN expression levels do not
correlate with responsiveness to immunomodulatory drugs across
MM cell lines (72). Among six cell lines that are resistant to im-
munomodulatory drugs, only two, RPMI-8226 and KMS11, ex-
press low levels of CRBN protein. In striking contrast, the other
four intrinsically resistant cell lines (KMS34, LP-1, KMS12BM,
and JJN-3) have higher basal levels of CRBN than the immuno-
modulatory drug-sensitive MM cell lines (72), suggesting that
other factors, possibly including p97 and its adaptors, play a crit-
ical role in regulating the CRBN-dependent anti-myeloma activity
of immunomodulatory drugs.
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